Deferiprone
Agranulocytosis/Neutropenia
- Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
- Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor ANC weekly on therapy.
- Interrupt deferiprone therapy if neutropenia develops.
- Interrupt deferiprone therapy if infection develops, and monitor the ANC more frequently.
- Advise patients taking deferiprone to report immediately any symptoms indicative of infection.
Patient Counseling Information
Medication Guides
Package Inserts
Updated January 2018